NDAORALTABLET
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
6/8 — Strong
ARICEPT (donepezil hydrochloride) by Eisai is alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Approved for dementia of the alzheimer’s type. First approved in 2010.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARICEPT (donepezil hydrochloride) is an oral small-molecule acetylcholinesterase inhibitor approved for Alzheimer's disease. It works by increasing acetylcholine levels in the brain to improve cognitive function and slow disease progression. The drug is administered as a tablet and has been a cornerstone therapy in dementia treatment for over a decade.
LOE Approaching0mo to LOE
Product faces imminent patent expiration in October 2026 with minimal time to capture additional value, signaling reduced brand team investment and potential workforce rationalization.
Mechanism of Action
Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition…
Indications (1)
Clinical Trials (20)
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).
Started Apr 2015
591 enrolled
Dementia With Lewy Body Disease
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
Started Mar 2015
2,231 enrolled
Alzheimer's Disease
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
Started Mar 2015
160 enrolled
Dementia, Lewy BodyLewy Body Disease
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
Started Jul 2014
532 enrolled
Alzheimer's Disease
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
Started Aug 2013
302 enrolled
Dementia Associated With Cerebrovascular Disease
Worked on ARICEPT at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.